Reduction of Rocuronium-induced Injection Pain With Aspiration of Blood

Anesthesia, General Clinical Trial

Official title:

Reduction of Rocuronium-induced Injection Pain With Aspiration of Blood

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06150001
• Other study ID #: 202301309A3
• Status: Not yet recruiting
• Phase: N/A
• Start date: December 2023
• Est. completion date: September 2024

Study information

• Verified date: November 2023
• Source: Chang Gung Memorial Hospital
• Contact: YI JU LIN
• Phone: +886978989223
• Email: ali840813[@]gmail.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of this clinical trial is to learn about reduction of rocuronium injection pain in participants receiving general anesthesia. The main question aims to answer is whether diluting rocuronium with blood can reduce rocuronium injection pain. Rocuronium is a rapid onset muscle relaxant used in general anesthesia. Lidocaine is a local anesthetic. Researchers will

• inject diluted rocuronium in participant's intravenous catheter during induction. • record withdrawal movement and rocuronium onset time and duration measured by train-of-four (TOF).

Researchers will compare between rocuronium diluted with blood, lidocaine and normal saline to see if blood can reduce rocuronium injection pain.

Description:

This clinical trial uses a random table for sequential randomization, randomly assigning subjects to 3 groups, each consisting of 40 participants.

Researcher will confirm the patency of peripheral intravenous lines before induction. If peripheral intravenous lines cannot be used, they will be readministered at another injection site. If there are difficulties in peripheral intravenous injection, the participant will need to withdraw from this clinical trial. The neuromuscular monitoring device (NMT) is installed before the start of the clinical trial to monitor the effects of the drug. To avoid influencing the final results, fentanyl and 2%lidocaine will not be administered before injecting rocuronium. Anesthesia induction begins with the administration of oxygen through a mask to assist breathing. Initially, propofol is injected at a dose of 1.5 to 2mg/kg. Once the participant is confirmed to have lost consciousness, researchers will inject diluted rocuronium immediately, with an injection speed of 10 to 15 seconds. The dose of rocuronium for each participant is 0.8 mg/kg. The first group is pre-diluted with 2mL of normal saline, the second group with 2mL of 2%lidocaine, and the third group with 2mL of the participant's blood. To avoid clotting of blood, the procedure of the third group involves using a syringe containing rocuronium to withdraw 2mL of blood from the vein, followed by simultaneous injection into the intravenous line. The NMT is used to monitor the drug's effects, defining the onset time as the time from rocuronium injection to the disappearance of train-of-four (TOF) count T1 and the duration of action as the time from rocuronium injection to the appearance of TOF count T1.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 120
• Est. completion date: September 2024
• Est. primary completion date: July 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Willing to sign the written informed consent form.

• Males and females aged 18 to 65.

• Undergoing endotracheal intubation under general anesthesia.

• Anesthesia physical status classification II or below.

Exclusion Criteria:

• estimated glomerular filtration rate less than 60

• History of cirrhosis or liver failure

• Neuromuscular disease or neurological symptoms

• Mental illness

• Arrhythmia

Related Conditions & MeSH terms

• Anesthesia, General

Intervention

Drug:
• rocuronium-normal-saline mixture
rocuronium will be pre-diluted with 2mL of normal saline. Researchers will inject the mixture into intravenous catheter.
• rocuronium-lidocaine mixture
rocuronium will be pre-diluted with 2mL of 2%lidocaine. Researchers will inject the mixture into intravenous catheter.
• rocuronium-blood mixture
Researchers will connect a syringe which contains 0.8mg/kg of rocuronium intravenous catheter, and then withdraw blood into the syringe. Finally inject the mixture into intravenous catheter.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Chang Gung Memorial Hospital

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	withdrawal movement by 4-point-scale	withdrawal movement is measured by 4-point-scale. Zero is equivalent to no withdrawal movement. One is equivalent to withdrawal movement involving wrist joint. Two is equivalent to withdrawal movement involving elbow joint. Three is equivalent to withdrawal movement involving shoulder joint	From enrollment to the end of assessment at thirty minutes.
Secondary	onset time	onset time is defined by injection of rocuronium mixture to the disappearance of Train-of-four count T1.	From enrollment to the end of assessment at 3 minutes.
Secondary	duration of action	Duration of action is defined by injection of rocuronium mixture to appearance of Train-of-four count T1.	From enrollment to the end of assessment at one hour.